GLP-1 RAs in Chronic Migraine

Investigators evaluate health care utilization and treatment patterns vs topiramate in an active-comparator study.

1

GLP-1 receptor agonists were associated with lower emergency department visits and hospitalizations compared to topiramate in chronic migraine patients.
2

The study included 10,997 patients in each cohort, with a mean age of 48 years and 88% being female.
3

Patients initiating GLP-1 RAs had a lower risk of nerve block procedures and triptan prescriptions compared to those on topiramate.
4

GLP-1 RA users were less likely to start additional preventive medications, including valproate and CGRP monoclonal antibodies.
5

The study highlights the need for randomized controlled trials to assess the preventive efficacy of GLP-1 RAs in migraine.

1